The FDA has recorded a supplement to abbreviated new drug application ANDA 216385 for nitrofurantoin, held by Novitium Pharma, dated 4 September 2026. An ANDA supplement is a change to an existing generic application - manufacturing, labelling or similar. It is not a new approval, not a new indication, and not a safety communication.
It is worth one paragraph only because generic supply actions are the mechanism by which an old, cheap, narrow-spectrum agent stays available, and nitrofurantoin's clinical value now rests on exactly that. It remains a first-line option for uncomplicated lower urinary tract infection in women, with the specific advantage that it concentrates in urine without the collateral selection pressure of a fluoroquinolone or a third-generation cephalosporin.
The prescribing caveats have not changed and are worth restating because they are the commonest errors: it does not treat pyelonephritis or any upper tract or systemic infection, because tissue concentrations are inadequate; it should be avoided when the estimated glomerular filtration rate is below about 30 mL/min, where efficacy falls and toxicity risk rises; and long-term use carries pulmonary and hepatic toxicity that presents insidiously in older patients.
- Reserve nitrofurantoin for uncomplicated lower urinary tract infection - never for pyelonephritis or sepsis
- Check renal function before prescribing; avoid below roughly 30 mL/min
- Ask about breathlessness or dry cough in anyone on long-term prophylaxis
- Prefer it over fluoroquinolones for simple cystitis where the isolate is susceptible
- Check local susceptibility data - resistance patterns for Escherichia coli vary widely between Indian centres
Why it matters
Generic supply actions are what keep narrow-spectrum options on the shelf, and the narrow-spectrum option is the one stewardship depends on.
Don't overread it
A generic application supplement is an administrative action - not a new indication, and not a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free